Citations

Clear

168 citation(s) found for "Perlmutter, J".

Pooling Prospective Studies to Investigate the Etiology of Second Cancers
Black, Amanda , Gibson, Todd M. , Park, Yikyung , Weinstein, Stephanie J. , Andreotti, Gabriella , Purdue, Mark P. , Fraumeni, Joseph F., Hartge, Patricia, Tucker, Margaret A. , Hoover, Robert N. , Cerhan, James R. , Zeleniuch‐Jacquotte, Anne , Curtis, Rochelle E. , Elena, Joanne W. , González, Amy Berrington de , Morton, Lindsay M. , Shiels, Meredith S. , Robien, Kim , Albanes, Demetrius , Freeman, Laura E. Beane , Sampson, Joshua N. , Cerhan, James R , Morton, Lindsay M , Berrington de Gonzalez, Amy , Gibson, Todd , Zeleniuch-Jacquotte, Anne

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | May 15, 2014 | Volume: 23 | Issue: 8 | Pages: 1598-1608

10.1158/1055-9965.epi-14-0191 | PMID 24832874 Get It

Abstract Background: With over 13 million cancer survivors in the United States today, second cancers are of rapidly growing importance. However, data on nontreatment risk factors for second cancers are sparse. We explored the feasibility of pooling data from cohort studies of cancer incidence to investigate second cancer etiology. Methods: We combined data from five prospective studies including more than 800,000 individuals. We compared study designs and populations; evaluated availability of and ability to harmonize risk factor data; compared incidence and survival for common first primary malignancies and incidence of second primary malignancies; and estimated sample size requirements. Results: Overall, 96,513 incident, first primary malignancies were diagnosed during 1985 to 2009. Incidence rates and survival following the first primary varied among the cohorts, but most of the heterogeneity could be explained by characteristics of the study populations (age, sex, smoking, and screening rates). A total of 7,890 second primary cancers (excluding original primary site) were identified, yielding sufficient statistical power (≥80%) for detecting modest associations with risk of all second cancers among survivors of common first primary malignancies (e.g., colorectal cancer); however, there were insufficient events for studying survivors of rarer cancers or identifying risk factors for specific second cancers. Conclusions: Pooling data from cohort studies to investigate nontreatment risk factors for second primary cancers seems feasible but there are important methodologic issues—some of which are barriers to specific research questions—that require special attention. Impact: Increased understanding of nontreatment risk factors for second cancers will provide valuable prevention and surveillance information. Cancer Epidemiol Biomarkers Prev; 23(8); 1598–608. ©2014 AACR.
Recommendations on Disease Management for Patients With Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer and Brain Metastases: American Society of Clinical Oncology Clinical Practice Guideline
Ramakrishna, Naren , Temin, Sarah , Chandarlapaty, Sarat , Crews, Jennie R. , Davidson, Nancy E. , Esteva, Francisco J. , Giordano, Sharon H. , González-Angulo, Ana M. , Kirshner, Jeffrey J., Krop, Ian E. , Levinson, Jennifer, Modi, Shanu , Patt, Debra A. , Perez, Edith A. , Perlmutter, Jane , Krop, Ian, Winer, Eric P. , Lin, Nancy U. , Modi, Shanu

Mayo Clinic

Journal of Clinical Oncology | May 6, 2014 | Volume: 32 | Issue: 19 | Pages: 2100-2108

10.1200/jco.2013.54.0955 | PMID 24799487 Get It

Purpose To provide formal expert consensus–based recommendations to practicing oncologists and others on the management of brain metastases for patients with human epidermal growth factor receptor 2 (HER2) –positive advanced breast cancer. Methods The American Society of Clinical Oncology (ASCO) convened a panel of medical oncology, radiation oncology, guideline implementation, and advocacy experts and conducted a systematic review of the literature. When that failed to yield sufficiently strong quality evidence, the Expert Panel undertook a formal expert consensus–based process to produce these recommendations. ASCO used a modified Delphi process. The panel members drafted recommendations, and a group of other experts joined them for two rounds of formal ratings of the recommendations. Results No studies or existing guidelines met the systematic review criteria; therefore, ASCO conducted a formal expert consensus–based process. Recommendations Patients with brain metastases should receive appropriate local therapy and systemic therapy, if indicated. Local therapies include surgery, whole-brain radiotherapy, and stereotactic radiosurgery. Treatments depend on factors such as patient prognosis, presence of symptoms, resectability, number and size of metastases, prior therapy, and whether metastases are diffuse. Other options include systemic therapy, best supportive care, enrollment onto a clinical trial, and/or palliative care. Clinicians should not perform routine magnetic resonance imaging (MRI) to screen for brain metastases, but rather should have a low threshold for MRI of the brain because of the high incidence of brain metastases among patients with HER2-positive advanced breast cancer.
A Randomized Clinical Trial of High-Dosage Coenzyme Q10 in Early Parkinson Disease
Investigators, The Parkinson Study Group QE3, Beal, M. Flint, Oakes, David , Shoulson, Ira , Henchcliffe, Claire , Galpern, Wendy R., Haas, Richard , Juncos, Jorge L., Nutt, John G. , Voss, Tiffini, Ravina, Bernard, Shults, Clifford M., Helles, Karen, Snively, Victoria, Lew, Mark, Griebner, Brian, Watts, Arthur, Gao, Shan , Pourcher, Emmanuelle, Bond, Louisette, Kompoliti, Katie , Sia, Cherissa, Jog, Mandar , Sultana, Munira , Kurlan, Roger, Richard, Irene Hegeman, Deeley, Cheryl, Waters, Cheryl , Figueroa, Angel, Arkun, Ani, Brodsky, Matthew , Ondo, William G. , Hunter, Christine , Jimenez‐Shahed, Joohi , Palao, Alicia, Miyasaki, Janis M. , So, Julie , Tetrud, James W., Reys, Liza, Singer, Carlos , Blenke, Anita, Russell, David , Cotto, Candace, Lannon, Margaret C., Drasby, Edward, Kumar, Rajeev , Subramanian, Thyagarajan , Ford, Donna Stuppy, Grimes, David A. , Côté, Diane , Conway, Jennifer, Siderowf, Andrew , Evatt, Marian L., Sommerfeld, Barbara, Lieberman, Abraham, Okun, Michael S. , Rodriguez, Ramon L. , Merritt, Stacy, Swartz, Camille, Martin, W. R. Wayne , King, Pamela, Stover, Natividad , Guthrie, Stephanie, Watts, Ray L., Fernandez, Hubert H. , Winters, Adrienna, Dawson, Ted M. , Dunlop, Becky, Feigin, Andrew, Shannon, Barbara , Nirenberg, Melissa J. , Ogg, Mattson , Ellias, Samuel A., Thomas, Cathi-Ann, Frei, Karen , Bódis-Wollner, Iván , Glazman, Sofya, Mayer, Thomas A. , Hauser, Robert A. , Langhammer, April, Ranawaya, Ranjit, Derwent, Lorelei, Farrow, Buff, Prakash, Rajan , Litvan, Irene , Robinson, Annette, Sahay, Alok , Gartner, Maureen, Markind, Samuel, Pelikan, Melisa, Hartlein, Johanna M, Molho, Eric , Evans, Sharon, Duffy, Amy, Lind, Marlene, Elmer, Lawrence , Davis, Kathy, Spears, Julia, Leehey, Maureen A. , Hermanowicz, Neal , Niswonger, Shari, Shill, Holly A. , Obradov, Sanja, Rajput, Alex, Cowper, Marilyn, Lessig, Stephanie, Fontaine, Deborah, Zadikoff, Cindy , Williams, Karen, Blindauer, Karen, Bergholte, Jo, Propsom, Clara Schindler, Stacy, Mark, Field, Joanne, Mihaila, Dragos, Chilton, Mark, Uc, Ergun Y., Sieren, Jeri, Simon, David K. , Kraics, Lauren, Silver, Althea, Boyd, James T. , Hamill, Robert W., Ingvoldstad, Christopher T., Young, Jennifer , Thomas, Karen, Kostyk, Sandra K. , Wojcieszek, Joanne, Pfeiffer, Ronald F. , Panisset, Michel , Beland, Monica, Reich, Stephen G. , Cines, Michelle, Zappala, Nancy, Rivest, J., Zweig, Richard M., Lumina, L. Pepper, Hilliard, Colette Lynn, Grill, Stephen , Kellermann, Marye, Tuite, Paul , Rolandelli, Susan, Kang, Un Jung , Young, Joan, Rao, Jayaraman, Cook, Maureen, Severt, Lawrence, Boyar, Karyn, Scott, Ingrid U. , Investigators, The Parkinson Study Group QE3, Beal, M. Flint , Agarwal, Pinky , Cole, Linda C. , Smith, Katharine , Friedman, Joseph H. , Zhang, Lin , Ahmed, Anwar E. , Mari, Zoltan K. , Pahwa, Rajesh , Sethi, Kapil D. , Hinson, Vanessa K. , Perlmutter, Joel S. , Adler, Charles H. , Wilson, Stephanie M. G. , Song, David , Williams, Karen, Uc, Ergun Y., Okun, Michael S , Litvan, Irene , Hauser, Robert A , Jimenez-Shahed, Joohi

Mayo Clinic

JAMA Neurology | March 25, 2014 | Volume: 71 | Issue: 5 | Pages: 543

10.1001/jamaneurol.2014.131 | PMID 24664227 Get It

A rare sequence variant in intron 1 of THAP1 is associated with primary dystonia
Vemula, Satya R. , Xiao, Jianfeng , Zhao, Yu , Bastian, Robert W., Racette, Brad A. , Paniello, Randal C., Uitti, Ryan J. , Gerpen, Jay A. van, Hedera, Peter , Truong, Daniel , Blitzer, Andrew , Rudzińska, Monika , Momčilović, Dragana, Frei, Karen , Pfeiffer, Ronald F. , LeDoux, Mark S. , Van Gerpen, Jay A, Perlmutter, Joel S. , Wszołek, Zbigniew K. , Jinnah, H. A. , Rudzinska-Bar, Monika

Mayo Clinic

Molecular Genetics & Genomic Medicine | February 12, 2014 | Volume: 2 | Issue: 3 | Pages: 261-272

10.1002/mgg3.67 | PMID 24936516 Get It

AbstractAlthough coding variants in THAP1 have been causally associated with primary dystonia, the contribution of noncoding variants remains uncertain. Herein, we examine a previously identified Intron 1 variant (c.71+9C>A, rs200209986). Among 1672 subjects with mainly adult‐onset primary dystonia, 12 harbored the variant in contrast to 1/1574 controls (P < 0.01). Dystonia classification included cervical dystonia (N = 3), laryngeal dystonia (adductor subtype, N = 3), jaw‐opening oromandibular dystonia (N = 1), blepharospasm (N = 2), and unclassified (N = 3). Age of dystonia onset ranged from 25 to 69 years (mean = 54 years). In comparison to controls with no identified THAP1 sequence variants, the c.71+9C>A variant was associated with an elevated ratio of Isoform 1 (NM_018105) to Isoform 2 (NM_199003) in leukocytes. In silico and minigene analyses indicated that c.71+9C>A alters THAP1 splicing. Lymphoblastoid cells harboring the c.71+9C>A variant showed extensive apoptosis with relatively fewer cells in the G2 phase of the cell cycle. Differentially expressed genes from lymphoblastoid cells revealed that the c.71+9C>A variant exerts effects on DNA synthesis, cell growth and proliferation, cell survival, and cytotoxicity. In aggregate, these data indicate that THAP1 c.71+9C>A is a risk factor for adult‐onset primary dystonia.
International Myeloma Working Group Consensus Statement for the Management, Treatment, and Supportive Care of Patients With Myeloma Not Eligible for Standard Autologous Stem-Cell Transplantation
Palumbo, Antonio , Miguel, Jesús F. San , Larocca, Alessandra , Niesvizky, Rubén, Morgan, Gareth J. , Hájek, Roman , Dimopoulos, Meletios Α. , Richardson, Paul G. , Cavo, Michèle , Spencer, Andrew , Stewart, A. Keith, Shimizu, Kazuyuki , Sonneveld, Pieter , Durie, Brian G.M. , Moreau, Philippe , Orlowski, Robert Z. , Rajkumar, S. Vincent , Landgren, Ola , Einsele, Hermann , Anderson, Kenneth C. , Richardson, Paul Gerard Guy , Lonial, Sagar , Orlowski, Robert Z. , Hajek, Roman , Dimopoulos, Meletios A , Moreau, Philippe , San-Miguel, Jesus , Morgan, Gareth J

Mayo Clinic

Journal of Clinical Oncology | January 13, 2014 | Volume: 32 | Issue: 6 | Pages: 587-600

10.1200/jco.2013.48.7934 | PMID 24419113 Get It

Purpose To provide an update on recent advances in the management of patients with multiple myeloma who are not eligible for autologous stem-cell transplantation. Methods A comprehensive review of the literature on diagnostic criteria is provided, and treatment options and management of adverse events are summarized. Results Patients with symptomatic disease and organ damage (ie, hypercalcemia, renal failure, anemia, or bone lesions) require immediate treatment. The International Staging System and chromosomal abnormalities identify high- and standard-risk patients. Proteasome inhibitors, immunomodulatory drugs, corticosteroids, and alkylating agents are the most active agents. The presence of concomitant diseases, frailty, or disability should be assessed and, if present, treated with reduced-dose approaches. Bone disease, renal damage, hematologic toxicities, infections, thromboembolism, and peripheral neuropathy are the most frequent disabling events requiring prompt and active supportive care. Conclusion These recommendations will help clinicians ensure the most appropriate care for patients with myeloma in everyday clinical practice.
International Myeloma Working Group Recommendations for the Treatment of Multiple Myeloma–Related Bone Disease
Terpos, Evangelos , Morgan, Gareth J. , Dimopoulos, Meletios Α. , Lentzsch, Suzanne , Sezer, Orhan , García‐Sánz, Ramón , Shimizu, Kazuyuki , Turesson, Ingemar , Reiman, Tony , Merlini, Giampaolo , Spencer, Andrew , Leleu, Xavier , Cavo, Michèle , Munshi, Nikhil C. , Durie, Brian G.M. , Roodman, G. David, Drake, Matthew T. , Raje, Noopur , Jurczyszyn, Artur , Rajkumar, S. Vincent , Merlini, Giampaolo , Dimopoulos, Meletios A , Terpos, Evangelos , Garcia-Sanz, Ramon , Morgan, Gareth J

Mayo Clinic

Journal of Clinical Oncology | May 21, 2013 | Volume: 31 | Issue: 18 | Pages: 2347-2357

10.1200/jco.2012.47.7901 | PMID 23690408 Get It

Purpose The aim of the International Myeloma Working Group was to develop practice recommendations for the management of multiple myeloma (MM) –related bone disease. Methodology An interdisciplinary panel of clinical experts on MM and myeloma bone disease developed recommendations based on published data through August 2012. Expert consensus was used to propose additional recommendations in situations where there were insufficient published data. Levels of evidence and grades of recommendations were assigned and approved by panel members. Recommendations Bisphosphonates (BPs) should be considered in all patients with MM receiving first-line antimyeloma therapy, regardless of presence of osteolytic bone lesions on conventional radiography. However, it is unknown if BPs offer any advantage in patients with no bone disease assessed by magnetic resonance imaging or positron emission tomography/computed tomography. Intravenous (IV) zoledronic acid (ZOL) or pamidronate (PAM) is recommended for preventing skeletal-related events in patients with MM. ZOL is preferred over oral clodronate in newly diagnosed patients with MM because of its potential antimyeloma effects and survival benefits. BPs should be administered every 3 to 4 weeks IV during initial therapy. ZOL or PAM should be continued in patients with active disease and should be resumed after disease relapse, if discontinued in patients achieving complete or very good partial response. BPs are well tolerated, but preventive strategies must be instituted to avoid renal toxicity or osteonecrosis of the jaw. Kyphoplasty should be considered for symptomatic vertebral compression fractures. Low-dose radiation therapy can be used for palliation of uncontrolled pain, impending pathologic fracture, or spinal cord compression. Orthopedic consultation should be sought for long-bone fractures, spinal cord compression, and vertebral column instability.
Developing Safety Criteria for Introducing New Agents into Neoadjuvant Trials
Berry, Donald A. , Zujewski, JoAnne, Hunsberger, Sally , Rubinstein, Larry , Tomaszewski, Joseph E. , Kelloff, Gary, Perlmutter, Jane , Buxton, Meredith , Lyandres, Julia, Albain, Kathy S. , Benz, Chris, Chien, A. Jo , Haluska, Paul , Leyland‐Jones, Brian , Liu, Minetta C. , Olopade, Olufunmilayo I. , Park, John W., Parker, Barbara A. , Yee, Douglas , DeMichele, Angela , Zujewski, Jo Anne , Münster, Pamela N. , Pusztai, Lajos , Tripathy, Debu , Rugo, Hope S. , Esserman, Laura J. , Olopade, Olufunmilayo I , Yee, Douglas , Rubinstein, Larry V

Mayo Clinic

Clinical Cancer Research | March 8, 2013 | Volume: 19 | Issue: 11 | Pages: 2817-2823

10.1158/1078-0432.ccr-12-2620 | PMID 23470967 Get It

Abstract New approaches to drug development are critically needed to lessen the time, cost, and resources necessary to identify and optimize active agents. Strategies to accelerate drug development include testing drugs earlier in the disease process, such as the neoadjuvant setting. The U.S. Food and Drug Administration (FDA) has issued guidance designed to accelerate drug approval through the use of neoadjuvant studies in which the surrogate short-term endpoint, pathologic response, can be used to identify active agents and shorten the time to approval of both efficacious drugs and biomarkers identifying patients most likely to respond. However, this approach has unique challenges. In particular, issues of patient safety are paramount, given the exposure of potentially curable patients to investigational agents with limited safety experience. Key components to safe drug development in the neoadjuvant setting include defining a study population at sufficiently poor prognosis with standard therapy to justify exposure to investigational agents, defining the extent and adequacy of safety data from phase I, detecting potentially harmful interactions between investigational and standard therapies, improving study designs, such as adaptive strategies, that limit patient exposure to ineffective agents, and intensifying safety monitoring in the course of the trial. The I-SPY2 trial is an example of a phase II neoadjuvant trial of novel agents for breast cancer in which these issues have been addressed, both in the design and conduct of the trial. These adaptations of phase II design enable acceleration of drug development by reducing time and cost to screen novel therapies for activity without compromising safety. Clin Cancer Res; 19(11); 2817–23. ©2013 AACR.
Genome-wide association study of survival in patients with pancreatic adenocarcinoma
Wu, Chen , Steplowski, Emily, Brotzman, Michelle, Xu, Mousheng, Mudgal, Poorva, Ámundadóttir, Laufey T. , Arslan, Alan A. , Bueno‐de‐Mesquita, H. Bas, Gross, Myron D., Helzlsouer, Kathy J., Jacobs, Eric J. , Petersen, Gloria M. , Zheng, Wei , Buring, Julie E. , Canzian, Federico , Cao, Guangwen , Duell, Eric J. , Elena, Joanne W. , Gaziano, J. Michael , Giovannucci, Edward L. , Hallmans, Göran, Hutchinson, Amy , Hunter, David J., Jenab, Mazda , Jiang, Guoliang , LaCroix, Andrea Z. , Li, Zhaoshen , Mendelsohn, Julie B., Panico, Salvatore , Patel, Alpa V. , Qian, Zhi Rong , Ríboli, Elio , Sesso, Howard D. , Shen, Hongbing , Shu, Xiao‐Ou , Tjønneland, Anne , Tobias, Geoffrey S. , Trichopoulos, Dimitrios, Virtamo, Jarmo, Visvanathan, Kala , Wactawski‐Wende, Jean , Wang, Chengfeng , Yu, Kai , Zeleniuch‐Jacquotte, Anne , Hoover, Robert N. , Hartge, Patricia, Fuchs, Charles S. , Lin, Dongxin , Wolpin, Brian M. , Kraft, Peter , Stolzenberg‐Solomon, Rachael Z. , Kooperberg, Charles , Albanes, Demetrius , Boutron‐Ruault, Marie‐Christine , Khaw, Kay‐Tee , Chanock, Stephen Jacob , Amundadottir, Laufey , Duell, Eric J , Arslan, Alan A , Canzian, Federico , Tjønneland, Anne , Wactawski-Wende, Jean , Shu, Xiao-Ou , Visvanathan, Kala , Jenab, Mazda , Zheng, Wei , Cao, Guangwen , Riboli, Elio , Zeleniuch-Jacquotte, Anne , Shen, Hongbing

Mayo Clinic

Gut | November 24, 2012 | Volume: 63 | Issue: 1 | Pages: 152-160

10.1136/gutjnl-2012-303477 | PMID 23180869 Get It

Background and objective Survival of patients with pancreatic adenocarcinoma is limited and few prognostic factors are known. We conducted a two-stage genome-wide association study (GWAS) to identify germline variants associated with survival in patients with pancreatic adenocarcinoma. Methods We analysed overall survival in relation to single nucleotide polymorphisms (SNPs) among 1005 patients from two large GWAS datasets, PanScan I and ChinaPC. Cox proportional hazards regression was used in an additive genetic model with adjustment for age, sex, clinical stage and the top four principal components of population stratification. The first stage included 642 cases of European ancestry (PanScan), from which the top SNPs (p≤10 −5 ) were advanced to a joint analysis with 363 additional patients from China (ChinaPC). Results In the first stage of cases of European descent, the top-ranked loci were at chromosomes 11p15.4, 18p11.21 and 1p36.13, tagged by rs12362504 (p=1.63×10 −7 ), rs981621 (p=1.65×10 −7 ) and rs16861827 (p=3.75×10 −7 ), respectively. 131 SNPs with p≤10 −5 were advanced to a joint analysis with cases from the ChinaPC study. In the joint analysis, the top-ranked SNP was rs10500715 (minor allele frequency, 0.37; p=1.72×10 −7 ) on chromosome 11p15.4, which is intronic to the SET binding factor 2 (SBF2) gene. The HR (95% CI) for death was 0.74 (0.66 to 0.84) in PanScan I, 0.79 (0.65 to 0.97) in ChinaPC and 0.76 (0.68 to 0.84) in the joint analysis. Conclusions Germline genetic variation in the SBF2 locus was associated with overall survival in patients with pancreatic adenocarcinoma of European and Asian ancestry. This association should be investigated in additional large patient cohorts.
Activity enhances dopaminergic long-duration response in Parkinson disease
Kang, Un Jung , Auinger, Peggy , Fahn, Stanley, Oakes, David , Shoulson, Ira , Kieburtz, Karl, Rudolph, Alice, Seibyl, John , Olanow, C. Warren , Tanner, Caroline M., Schifitto, Giovanni , Zhao, Hongwei , Reyes, Lydia, Shinaman, Aileen, Comella, Cynthia L., Blasucci, Lucia M., Samanta, Johan, Stacy, Mark, Williamson, Kelli, Harrigan, Mary, Greene, Paul, Ford, Blair, Moskowitz, Carol, Truong, Daniel , Pathak, Mayank , Jankovic, Joseph, Ondo, William G. , Atassi, Farah, Hunter, Christine , Jacques, Carol, Lannon, Margaret C., Russell, David , Jennings, Danna , Fussell, B., Schwarzschild, Michael A. , Growdon, John H., Tennis, Marsha, Gauthier, Serge , Panisset, Michel , Hall, Jean, Gancher, Stephen T., Hammerstad, John P., Stone, Claudia, Alexander-Brown, Barbara, Molho, Eric , Brown, Diane, Evans, Sharon, Manyam, Bala V., Simpson, Patricia , Wulbrecht, Brian, Whetteckey, Jacqueline, Roberts, Ted E, King, Pamela, Zesiewicz, Theresa A. , Gauger, Lisa, Trugman, Joel M. , Wooten, G. Frederick, Rost‐Ruffner, Elke, Suchowersky, Oksana , Ranawaya, Ranjit, Wood, Susan M. , Pantella, Carol , Kurlan, Roger, Richard, Irene Hegeman, Pearson, N. Shirlene, Caviness, John N., Adler, Charles, Lind, Marlene, Siderowf, Andrew , Colcher, Amy, Lloyd, Mary, Weiner, William J., Shulman, Lisa M. , Koller, William C., Lyons, Kelly , Feldman, Robert G., Ellias, Samuel A., Thomas, Cathi-Ann, Juncos, Jorge L., Watts, Ray L., Partlow, Anna, Tetrud, James W., Togasaki, Daniel M., Stewart, Tracy, Mark, Margery H., Sage, Jacob I., Caputo, Debbie, Gould, Harry J. , Rao, Jayaraman, McKendrick, A. D., Brin, Mitchell F. , Danisi, Fabio , Benabou, Reina, Hubble, Jean, Paulson, George W., Reider, Carson, Birnbaum, Alex, So, Julie , Dubinsky, Richard , Uitti, Ryan J. , Turk, Margaret F., Rottenberg, David A., Hansen, Joy, Ramos, Serrano, Waters, Cheryl , Lew, Mark, Welsh, Mickie, Kawai, Connie, OʼBrien, Christopher , Kumar, Rajeev , Seeberger, Lauren , Judd, Deborah, Mendis, Tilak, Grimes, David A. , Sutherland, Laura, Dawson, Ted M. , Reich, Stephen G. , Frey, Kirk A. , Wernette, K., Marek, Kenneth , Lang, Anthony E. , Goetz, Christopher G. , Jankovic, Joseph, Friedman, Joseph H. , Standaert, David G. , Factor, Stewart Alan , Clark, Jeffrey N. , Martin, W. R. Wayne , Hauser, Robert A. , Perlmutter, Joel S. , Racette, Brad A. , Simuni, Tanya , Saint‐Hilaire, Marie , Miyasaki, Janis M. , Johnston, Lisa , Pahwa, Rajesh , Wszołek, Zbigniew K. , Tuite, Paul , Barclay, Corlane , Dunlop, Rebecca A. , Albin, Roger L.

Mayo Clinic

Neurology | March 30, 2012 | Volume: 78 | Issue: 15 | Pages: 1146-1149

10.1212/wnl.0b013e31824f8056 | PMID 22459675 Get It